TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06315322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam Film-coated tablet
Description: Drug: Brivaracetam Film-coated tablet Pharmaceutical form: Film-coated tablet Route of administration: Oral use Brivaracetam film-coated tablet \[10, 25 or 50 mg\] will be administered twice per day in equal doses.
Study: NCT05378659

Intervention type: BEHAVIORAL
Intervention: Stroop Test
Description: Evaluates Processing Speed and Executive Control

Intervention type: DIAGNOSTIC_TEST
Intervention: 4AT Delirium
Description: Screening tool to test for delirium post surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: 4AT Delirium
Description: Screening tool to test for delirium post surgery

Intervention type: BEHAVIORAL
Intervention: Grooved Pegboard
Description: Evaluation testing for dominant and non dominant sensory-motor speed

Intervention type: BEHAVIORAL
Intervention: Grooved Pegboard
Description: Evaluation testing for dominant and non dominant sensory-motor speed

Intervention type: BEHAVIORAL
Intervention: NACC Cognitive Battery
Description: A series of tests that evaluate attention, concentration, immediate verbal memory, immediate visual memory, discrimination, processing/motor speed, and validity and effort.

Intervention type: BEHAVIORAL
Intervention: NACC Cognitive Battery
Description: A series of tests that evaluate attention, concentration, immediate verbal memory, immediate visual memory, discrimination, processing/motor speed, and validity and effort.

Intervention type: DIAGNOSTIC_TEST
Intervention: ERP Testing
Description: An event-related potential ( ERP) is the measured brain response that is the direct result of a specific sensory, cognitive, or motor event. More formally, it is any stereotyped electrophysiological response to a stimulus. The study of the brain in this way provides a noninvasive means of evaluating brain functioning.

Intervention type: DIAGNOSTIC_TEST
Intervention: ERP Testing
Description: An event-related potential ( ERP) is the measured brain response that is the direct result of a specific sensory, cognitive, or motor event. More formally, it is any stereotyped electrophysiological response to a stimulus. The study of the brain in this way provides a noninvasive means of evaluating brain functioning.
Study: NCT04615988

Intervention type: OTHER
Intervention: questionnaire completion, blood collection
Description: questionnaire provided to subject during study visits. One tube blood collected for research purposes at baseline
Study: NCT06315322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam oral solution
Description: Pharmaceutical form: Oral solution Route of administration: Oral use Brivaracetam oral solution \[10 mg/mL\]) will be administered twice per day in equal doses.
Study: NCT05378659

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Plasma and Serum sampling
Description: Up to six 4 ml samples of both serum and plasma will be obtained to assess for inflammatory markers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Plasma and Serum sampling
Description: Up to six 4 ml samples of both serum and plasma will be obtained to assess for inflammatory markers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral Spinal Fluid Sample
Description: At the time the spinal is placed for anesthetic purposes, 2ml of cerebral spinal fluid will be obtained to assess for inflammatory markers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral Spinal Fluid Sample
Description: At the time the spinal is placed for anesthetic purposes, 2ml of cerebral spinal fluid will be obtained to assess for inflammatory markers.
Study: NCT05301348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photoacoustic Flow Cytometry
Description: Detection of circulating blood clots
Study: NCT06352216

Intervention type: DIAGNOSTIC_TEST
Intervention: Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US); Haemophilia joint health score (HJHS)
Description: Each subject is examined for the presence of synovitis using the aforementioned diagnostics.
Study: NCT06209320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lower dose atropine sulfate eye drops
Description: administer to eyes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose atropine sulfate eye drops
Description: administer to eyes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: administer to eyes
Study: NCT06685107

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Analgesia
Description: Analgesia as determined by the treating physician

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Analgesia + Virtual Reality
Description: Analgesia as determined by the treating physician and Virtual Reality experience that will use a geriatric-focused VR platform that has age appropriate VR content and will run for approximately 5-10 minutes
Study: NCT06681896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MICROFIT - personalised high intensity interval training exercise rehabilitation and dietary advice
Description: MICROFIT is a 24-week long personalized one-on-one exercise and dietary education intervention, along with home exercise guided by personal trainers. Exercise intervention includes High Intensity Interval Training (HIIT) and dietary advice focuses on incorporation of a Mediterranean-type diet.~Phase 1 - Induction (8 weeks) Exercise: Twice-weekly 1-hour personal trainer (PT) supervised exercise sessions. 45 minute homework exercise session once a week.~Diet: 1-hour educational session with a dietician, followed by two 30-minute follow up sessions.~Phase 2 - Consolidation (10 weeks) Exercise: Once weekly 1 hour PT sessions, two 45 minute homework sessions once a week.~Diet: 30-minute sessions every 5 weeks.~Phase 3 - Maintenance (6 weeks) Exercise: Supervised 1 hour PT sessions once every 3 weeks, 45-minute homework sessions three times a week.~Diet: one final 30 minute session after week 3.
Study: NCT06682494

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Education
Description: Participants will receive traditional educational handouts focusing on increasing awareness of oral cancer risks, preventive strategies, and the importance of regular dental check-ups. Participants will be provided time to read the handouts based on calculated reading time.
Study: NCT05055661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical Teleconsultation
Description: The pharmacist will apply the teleconsultation according to the elaborated workflows and will follow in seven steps: scheduling the teleconsultation; pre-consultation, in which the pharmacist will make a checklist of the adequacy of the teleconsultation environment; presentation of the professional and the objectives of the teleconsultation to the patient; search for information about the patient and their pharmacotherapy; identification of problems related to pharmacotherapy; elaboration of a care plan and appointment for the re-consultation.
Study: NCT04468321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apple Watch
Description: Participants will be assigned to the Apple Watch arm to assess the impact of individual use of the Apple Watch on patient-reported and clinical utilization outcomes using Hugo.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Withings Move
Description: Participants will be assigned to the Withings Move arm to assess the impact of individual use of the Withings Move on patient-reported and clinical utilization outcomes using Hugo.
Study: NCT05909176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GYN Residency Training
Description: The combined care model will be implemented and during months 5-14.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Campaign
Description: The social media campaign will be implemented along with the combined care model in months 15-18.
Study: NCT06687889

Intervention type: OTHER
Intervention: Elastography Measurements
Description: Elastography Measurements

Intervention type: OTHER
Intervention: Elastography Measurements
Description: Elastography Measurements

Intervention type: OTHER
Intervention: Bone Mineral Density Measurement (DEXA)
Description: Bone Mineral Density Measurement (DEXA)

Intervention type: OTHER
Intervention: Bone Mineral Density Measurement (DEXA)
Description: Bone Mineral Density Measurement (DEXA)

Intervention type: OTHER
Intervention: Berg balance scale
Description: Berg balance scale

Intervention type: OTHER
Intervention: Berg balance scale
Description: Berg balance scale
Study: NCT06682494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI-powered Chatbox
Description: The chatbot interaction will be initiated through a provided link, allowing participants to access information and ask questions related to oral health and cancer prevention. The chatbot is programmed to provide accurate information on oral cancer risks, symptoms, preventive measures, and the importance of regular dental check-ups. Participants will be encouraged to interact with the chatbot for a specified duration
Study: NCT05236062

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: aerobic and resistance exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention control
Description: stretching
Study: NCT06095596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral upadacitinib 45mg/d for 8 weeks in the induction therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab 300mg intravenously on weeks 1, 2, 6, and then on every 8-week interval.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab
Description: Vedolizumab 300mg intravenously on weeks 1, 2, 6, and then on every 8-week interval.
Study: NCT06622668

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological NTLA-3001
Description: IV administration of AAV and CRISPR/Cas9 gene editing system
Study: NCT06179953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NAO intervention
Description: The protocol is divided into 4 stages:~1. EMOTION RECOGNITION - Mime Game: activity aimed at acquiring the ability to label basic emotions.~2. EMOTION/SITUATION ASSOCIATION - How do I feel when...? game: presentation of social situations to acquire the ability to attribute the emotion associated with the situation presented.~3. DIFFERENTIATION BETWEEN EMOTIONS AND THOUGHTS - Think-Feel Game: activity aimed at differentiating thoughts from emotions and acquiring the skill of linking a thought to an emotion.~4. LEARNING A REPERTOIRE OF USEFUL THOUGHTS: acquisition of useful thoughts related to certain emotional situations. The robot provides instructions and if the child requests it, it elects prompts.

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional intervention
Description: The protocol is divided into 4 stages:~1. EMOTION RECOGNITION - Mime Game: activity aimed at acquiring the ability to label basic emotions.~2. EMOTION/SITUATION ASSOCIATION - How do I feel when...? game: presentation of social situations to acquire the ability to attribute the emotion associated with the situation presented.~3. DIFFERENTIATION BETWEEN EMOTIONS AND THOUGHTS - Think-Feel Game: activity aimed at differentiating thoughts from emotions and acquiring the skill of linking a thought to an emotion.~4. LEARNING A REPERTOIRE OF USEFUL THOUGHTS: acquisition of useful thoughts related to certain emotional situations. The therapist provides instructions, and if the child has difficulty responding, he or she may ask the operator for prompts.
Study: NCT06626399

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of SSI
Description: Diagnosis of SSI by manual system in colorectal surgery procedures enrolled in the SSI surveillance programme.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of SSI
Description: Diagnosis of SSI by manual system in colorectal surgery procedures enrolled in the SSI surveillance programme.
Study: NCT05947084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula
Description: Growth Monitoring Study of Infant Formula fed to Healthy Term Infants over a 16 week period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula
Description: Growth Monitoring Study of Infant Formula fed to Healthy Term Infants over a 16 week period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula
Description: Growth Monitoring Study of Infant Formula fed to Healthy Term Infants over a 16 week period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant Formula
Description: Growth Monitoring Study of Infant Formula fed to Healthy Term Infants over a 16 week period
Study: NCT06696794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Description: When administering neoadjuvant intravesical instillations, instruct the patient to lie flat on the treatment bed and cover with a waterproof pad. Disinfect the perineal area 2-3 times. Under sterile conditions, insert a catheter and drain the bladder of urine completely. Slowly instill the prepared instillation solution (mitomycin) into the bladder. If the patient experiences pain during the instillation, stop the infusion immediately, and continue when the pain subsides. If the patient still cannot tolerate it, discontinue the instillation treatment for this session. After the medication is instilled into the bladder, the catheter can be removed immediately or left in place. Instruct the patient to hold their urine for as long as possible under suitable conditions for 2 hours, and to change positions intermittently while the medication is retained in the bladder. The neoadjuvant intravesical instillation cycle is twice (one day and 4 h before en-bloc surgery）

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (Placebo)
Description: When administering neoadjuvant intravesical instillations, instruct the patient to lie flat on the treatment bed and cover with a waterproof pad. Disinfect the perineal area 2-3 times. Under sterile conditions, insert a catheter and drain the bladder of urine completely. Slowly instill the prepared instillation solution (Normal Saline) into the bladder. If the patient experiences pain during the instillation, stop the infusion immediately, and continue when the pain subsides. If the patient still cannot tolerate it, discontinue the instillation treatment for this session. After the medication is instilled into the bladder, the catheter can be removed immediately or left in place. Instruct the patient to hold their urine for as long as possible under suitable conditions for 2 hours, and to change positions intermittently while the medication is retained in the bladder. The neoadjuvant intravesical instillation cycle is twice (one day and 4 h before en-bloc surgery）
Study: NCT06697990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iruplinalib
Description: 60 mg of Iruplinalib, once daily for 7 days, followed by 180 mg of Iruplinalib, once daily in a 28-days cycle.
Study: NCT06719609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ankle tape
Description: The influence of ankle tape on gait biomechanics
Study: NCT06478615

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coring out Fistulectomy with Closure of Internal Sphincter Opening
Description: The patient was laid in the lithotomy position. Skin preparation and draping were done. Normal saline irrigation was performed. The anal canal was sufficiently dilated to permit the introduction of a self-retaining retractor. With H2O2 injection into the fistula tract, the internal opening and tract of the fistula will be identified. The incision was made around the external opening, and the tract was all cored out along the tract from the external opening to the internal sphincter. Meticulous hemostasis will be performed, stay suture by PDS 4/0 around fistiolous opening at the internal sphincter, excision of fistulous tract above stay suture, then closure of internal sphincter defect by PDS 3/0. Anal packing with 4 × 4 epinephrine gauze and sterile protective dressing was performed. After the operation, a stool softener and pain controller were prescribed, and patients were discharged.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lay Open Fistulotomy and Primary Sphincter Repair
Description: Patients were put in a lithotomy position and the skin was then draped. After identification of the external fistula orifice probing of the fistula tract with identification of the fistulous tract and internal orifice with H2O2 injection into the fistula tract. The fistula was laid open and fistulectomy was then conducted and dissected with diathermy cautery help. Then Primary repair of the sphincter with PDS 3/0 with proper hemostasis using coagulation diathermy.
Study: NCT04635644

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Patients will be turned into the prone position. A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T8 spinous process. The erector spinae muscles will be identified superficial to the tip of the T8 transverse process. After local infiltration of the needle insertion site with 2-3 ml of 2% lidocaine, a 21G 10 cm needle will be inserted using an in-plane approach in a cranial to caudal direction to contact the T8 transverse process. The location of the needle tip will be confirmed by hydrodissection with 2 mL of lidocaine 2% and visualizing linear fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of 0.25% Bupivacaine is injected will be injected at this point. The same procedure will be repeated for the opposite side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: Patients will be placed on their right side. An intrathecal injection of morphine 200 μg (0.2 mL of morphine sulfate 1 mg/mL) diluted in 1.8 mL normal saline will be administered at the L3-L4 or L4-L5 level with a 25 G Whitacre spinal needle.
Study: NCT04806581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic Hepatocyte
Description: Allogeneic hepatocyte with cell numbers L,M,H respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic Hepatocyte
Description: Allogeneic hepatocyte with cell numbers L,M,H respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic Hepatocyte
Description: Allogeneic hepatocyte with cell numbers L,M,H respectively.
Study: NCT05282693

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ReMag
Description: 300 mg of ReMag dissolved in lemon flavor liquid

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lemon flavored liquid
Study: NCT05090358

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Properly formulated meals will be provided to both diet groups for the first 12 weeks to facilitate compliance in women with metastatic breast cancer prescribed alpelisib. After 12 weeks, subjects on the two dietary arms will be given the option to cross-over to the other diet arm and continue the prescribed dietary formulation. The decision to cross over will be per patient preference.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate Diet
Description: Properly formulated meals will be provided to both diet groups for the first 12 weeks to facilitate compliance in women with metastatic breast cancer prescribed alpelisib. After 12 weeks, subjects on the two dietary arms will be given the option to cross-over to the other diet arm and continue the prescribed dietary formulation. The decision to cross over will be per patient preference.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: The recommended dose of PIQRAY is 300 mg (two 150 mg film-coated tablets) taken orally, once daily, with food. Patients should take their dose of PIQRAY at approximately the same time each day.
Study: NCT06393530

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.9%sodium chloride
Description: Bilateral ESPB under ultrasound guidance (adjusted to the incision line): 2 x 20ml/kg 0,9% normal saline
Study: NCT05090358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: The recommended dose of PIQRAY is 300 mg (two 150 mg film-coated tablets) taken orally, once daily, with food. Patients should take their dose of PIQRAY at approximately the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: The recommended dose of PIQRAY is 300 mg (two 150 mg film-coated tablets) taken orally, once daily, with food. Patients should take their dose of PIQRAY at approximately the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: The recommended dose is 500 mg to be administered intramuscularly into the buttocks slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on days~1, 15, 29 and once monthly thereafter.
Study: NCT06393530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% ropivacaine
Description: Bilateral ESPB under ultrasound guidance (adjusted to the incision line): 2 x 20ml/kg 0,2% ropivacaine
Study: NCT05090358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: The recommended dose is 500 mg to be administered intramuscularly into the buttocks slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on days~1, 15, 29 and once monthly thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: The recommended dose is 500 mg to be administered intramuscularly into the buttocks slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on days~1, 15, 29 and once monthly thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Canagliflozin is an inhibitor of SGLT2, the transporter responsible for reabsorbing the majority of glucose filtered by the kidney. For the first week of canagliflozin dosing, the dose will be 100 mg. Starting week 2 and onward the dose will be 300 mg and supplied by the site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Canagliflozin is an inhibitor of SGLT2, the transporter responsible for reabsorbing the majority of glucose filtered by the kidney. For the first week of canagliflozin dosing, the dose will be 100 mg. Starting week 2 and onward the dose will be 300 mg and supplied by the site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Canagliflozin is an inhibitor of SGLT2, the transporter responsible for reabsorbing the majority of glucose filtered by the kidney. For the first week of canagliflozin dosing, the dose will be 100 mg. Starting week 2 and onward the dose will be 300 mg and supplied by the site.
Study: NCT06687889

Intervention type: OTHER
Intervention: Functional reach test
Description: Functional reach test

Intervention type: OTHER
Intervention: Functional reach test
Description: Functional reach test